A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Dallas, Texas 75390-8527, United States
Fort Worth, Texas 76104, United States
Houston, Texas 77030-4009, United States
Seattle, Washington 98109-1023, United States
Buenos Aires, Buenos Aires C1264AAA, Argentina
Rio Negro, Viedma 8500, Argentina
Hong Kong SAR, Hong Kong
Kitaadachi-gun, Saitama 362-0806, Japan
Chuo-ku, Tokyo 104-0045, Japan
Koto, Tokyo 135-8550, Japan
Niaosong Township, Taiwan 83301, Taiwan
Kuei-Shan Chiang, Taoyuan/ Taiwan ROC 33305, Taiwan
Liouying Township, Taiwan
East Yorkshire, HU16 5JQ, United Kingdom